MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
604.18%
Quick Ratio
604.18%
Cash Ratio
293.52%
Debt to Asset Ratio
19.12%
Unit: Thousand (K) dollars
Assets Breakdown
    • Long-term investments
    • Cash and cash equivalents
    • Short-term investments
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Operating lease liabilities, non...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
278,729
274,161
232,185
170,084
Short-term investments
249,864
196,277
228,753
327,750
Restricted cash and cash equivalents, current
1,929
1,925
1,922
2,215
Equity investments
4,133
5,861
6,077
8,679
Prepaid expenses and other current assets
39,084
44,761
45,143
36,956
Total current assets
573,739
522,985
514,080
545,684
Intangible assets, net
7,702
7,777
7,850
7,924
Goodwill
16,937
16,937
16,937
16,937
Property and equipment, net
50,430
53,158
55,620
58,203
Operating right-of-use assets
59,391
60,760
62,099
63,555
Restricted cash and cash equivalents, noncurrent
6,944
6,956
6,963
6,957
Long-term investments
475,016
332,970
314,575
304,212
Other assets
24,647
24,042
24,699
15,981
Total assets
1,214,806
1,025,585
1,002,823
1,019,453
Accounts payable
17,754
5,445
9,803
6,847
Accrued and other liabilities
77,207
68,113
83,012
68,375
Deferred revenue, current
-
-
-
0
Contingent consideration obligation, current
-
-
0
0
Total current liabilities
94,961
73,558
92,815
75,222
Deferred revenue, noncurrent
-
-
-
9,433
Operating lease liabilities, noncurrent
84,137
86,635
89,054
91,215
Contingent consideration obligation, noncurrent
34,340
33,210
34,100
34,180
Other long-term liabilities
18,875
19,417
21,578
13,305
Total liabilities
232,313
212,820
237,547
223,355
Common stock, 0.0001 par value 300,000,000 shares authorized as of june30, 2026 and december31, 2025 169,185,671 and 139,474,954 shares issued and outstanding as of june30, 2026 and december31, 2025, respectively
17
16
14
14
Additional paid-in capital
2,230,464
2,139,698
1,965,090
1,952,843
Accumulated other comprehensive loss
-4,602
-3,483
-2,057
-1,911
Accumulated deficit
-1,243,386
-1,323,466
-1,197,771
-1,154,848
Total stockholders equity
982,493
812,765
765,276
796,098
Total liabilities and stockholders equity
1,214,806
1,025,585
1,002,823
1,019,453
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$278,729K (32.03%↑ Y/Y)Short-term investments$249,864K (-35.54%↓ Y/Y)Prepaid expenses andother current assets$39,084K (-5.75%↓ Y/Y)Equity investments$4,133K (-43.15%↓ Y/Y)Restricted cash and cashequivalents, current$1,929K (-97.81%↓ Y/Y)Total current assets$573,739K (-22.02%↓ Y/Y)Long-term investments$475,016K (66.03%↑ Y/Y)Operating right-of-useassets$59,391K (-8.42%↓ Y/Y)Property and equipment,net$50,430K (-17.05%↓ Y/Y)Other assets$24,647K (86.89%↑ Y/Y)Goodwill$16,937K (0.00%↑ Y/Y)Intangible assets, net$7,702K (-3.70%↓ Y/Y)Restricted cash and cashequivalents, noncurrent$6,944K (-0.17%↓ Y/Y)Total assets$1,214,806K (1.87%↑ Y/Y)Total liabilities andstockholders equity$1,214,806K (1.87%↑ Y/Y)Total stockholdersequity$982,493K (3.70%↑ Y/Y)Total liabilities$232,313K (-5.20%↓ Y/Y)Accumulated deficit-$1,243,386K (-25.38%↓ Y/Y)Accumulated othercomprehensive loss-$4,602K (-107.20%↓ Y/Y)Additional paid-in capital$2,230,464K (14.89%↑ Y/Y)Total currentliabilities$94,961K (-9.56%↓ Y/Y)Operating leaseliabilities, noncurrent$84,137K (-9.92%↓ Y/Y)Contingent considerationobligation, noncurrent$34,340K (2.14%↑ Y/Y)Other long-termliabilities$18,875K (44.85%↑ Y/Y)Common stock, 0.0001par value...$17K (21.43%↑ Y/Y)Accrued and otherliabilities$77,207K (-6.60%↓ Y/Y)Accounts payable$17,754K (45.12%↑ Y/Y)

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (VIR)